secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001558370-24-008063
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Q1 net loss $17.2M; Gilead deal funds cash runway into Q2 2025
--------------------------------------------------------------------

- Net loss $17.2M in Q1 2024 vs $22.6M YoY; cash and equivalents $34.0M at March 31.
- In April 2024 received $30M upfront + $13.5M equity from Gilead; up to $592.5M in potential milestones.
- Plan to initiate Phase 2 trial for XTX101 (anti-CTLA-4) in MSS CRC in Q3 2024; data in Q4 2024.
- Discontinued XTX202 monotherapy; exploring combo development opportunities.
- Cash runway expected into Q2 2025, including $44.6M in April gross proceeds from Gilead and private placements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/0001558370-24-008063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/xlo-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer